Jack J. Fernandes developed Regenica's core belief while working on cancer therapies at Kite Pharma: Our answer to providing the world with innovative, affordable, and high-social-need therapies lies in reducing the time and cost of the drug and vaccine development process.
Our unique development model positions Regenica in a way never before seen in biotechnology. By enhancing an agile, entrepreneurial biotech model with the regulatory prowess and scaled efficiency of a government defense contractor, we can gain FDA approval for new therapies 5x faster and 100x cheaper than traditional biopharmaceutical models. Through a unique strategy of incentive-stacking and regulatory engineering, Regenica can transform abandoned, historically unprofitable, high-social-need therapies into attractive, risk-adjusted investment opportunities that can protect the world. Regenica has signed exclusive agreements with several world class research institutions, including UCLA, and is putting the finishing touches on a mixed 5-asset pipeline of medical countermeasures to biochemical terrorism. Fernandes wants to bring as many safe, affordable and effective medicines to the world as he can during his lifetime.
Check out Regenica Biosciences here.